{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "5bc6e093-da4b-47cd-9c09-5cd0695b4438",
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\n",
    "from spacy import displacy\n",
    "import diseaseprocessor\n",
    "import chemicalprocessor\n",
    "import class_entities"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "00f650ee-36b5-4764-a7ae-7348783e3ba4",
   "metadata": {},
   "outputs": [],
   "source": [
    "colors = {\"DISEASE\":\"linear-gradient(90deg, #aa9cfc, #fc9ce7)\",\n",
    "          \"CHEMICAL\":\"linear-gradient(90deg, #43C6AC, ##F8FFAE)\"}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "0f45b382-962e-4a07-bf19-b6bc186ac83d",
   "metadata": {},
   "outputs": [],
   "source": [
    "disease_service = diseaseprocessor.DiseaseProcessor('./models/Disease')\n",
    "chemical_service = chemicalprocessor.ChemicalProcessor('./models/Chemical')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "60532aec-c500-47c8-9d44-70cfd6d5255a",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('prueba_comb.txt','r') as f:\n",
    "    sequence = f.read()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "ad1daa4e-a064-402d-a589-5299691e7d0a",
   "metadata": {},
   "outputs": [],
   "source": [
    "nlp = spacy.load(\"en_core_web_sm\")\n",
    "doc = nlp(sequence)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "649f4417-33aa-4382-ad45-d067b8eeb184",
   "metadata": {},
   "outputs": [],
   "source": [
    "def paragraphs(document):\n",
    "    start = 0\n",
    "    for token in document:\n",
    "        if token.is_space and token.text.count(\"\\n\") > 1:\n",
    "            yield document[start:token.i]\n",
    "            start = token.i\n",
    "    yield document[start:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "cbfb8848-e25d-44a6-bdca-b33a6072e755",
   "metadata": {},
   "outputs": [],
   "source": [
    "def remove_non_entities(entities):\n",
    "    for ent in entities.ents:\n",
    "        if ent['entity_group'] == '0':\n",
    "            entities.ents.remove(ent)\n",
    "\n",
    "def correct_boundaries(entities):\n",
    "    last_ent = {'entity_group': '0', 'score': 1, 'word': '', 'start': 0, 'end': 0}\n",
    "    for ent in entities.ents:\n",
    "        if ent['entity_group'] == last_ent['entity_group']:\n",
    "            if ent['start'] == last_ent['end']:\n",
    "                ent['start'] = last_ent['start']\n",
    "                if ent['word'].startswith('##'):\n",
    "                    ent['word'] = ent['word'].replace('##', '')\n",
    "                ent['word'] = last_ent['word'] + ent['word']\n",
    "                # print('NEW BOUNDARIES:')\n",
    "                print(ent)\n",
    "                entities.ents.remove(last_ent)\n",
    "                # print('------------------')\n",
    "        last_ent = ent   \n",
    "\n",
    "def ents_spans_spacy_doc(entities):\n",
    "    ent_spans =[]\n",
    "    for ent in entities.ents:\n",
    "        proposed_ent = doc.char_span(ent['start'],ent['end'],ent['entity_group'])\n",
    "        if proposed_ent:\n",
    "            ent_spans.append(proposed_ent)\n",
    "    return ent_spans\n",
    "\n",
    "def solve_split_words(entities,ent_spans):\n",
    "    proposed_ents = []\n",
    "    for i,ent in enumerate(entities.ents):\n",
    "        proposed_ent = doc.char_span(ent['start'],ent['end'],ent['entity_group'])\n",
    "        if not proposed_ent:\n",
    "            proposed_ents.append(ent)\n",
    "            #print(ent)\n",
    "\n",
    "    #new_ent=None      \n",
    "    for i,ent in enumerate(proposed_ents):     \n",
    "        if ent['word'].startswith('##'):\n",
    "            if proposed_ents[i-1]['entity_group'] == ent['entity_group']:\n",
    "                if (ent['start'] - proposed_ents[i-1]['end'])<10:\n",
    "                    new_ent = doc.char_span(proposed_ents[i-1]['start'],ent['end'],ent['entity_group'])\n",
    "                    print(new_ent)\n",
    "                    ent_spans.append(new_ent)\n",
    "    \n",
    "    return ent_spans"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "be009ad2-4b39-49f2-9b7c-0cd7dd45e73c",
   "metadata": {},
   "outputs": [],
   "source": [
    "def postprocessing(doc,entities):\n",
    "    remove_non_entities(entities)\n",
    "    correct_boundaries(entities)\n",
    "    ent_spans = ents_spans_spacy_doc(entities)\n",
    "    ent_spans = solve_split_words(entities, ent_spans)\n",
    "    ent_spans = list(filter(None, ent_spans))\n",
    "    ents = doc.set_ents(ent_spans)\n",
    "    print(doc.ents)\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "d269f517-79c5-458f-a5a6-800a6d013452",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "53778\n"
     ]
    }
   ],
   "source": [
    "print(len(str(doc)))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3f5b3209-0bea-42f9-8caf-2941571998ad",
   "metadata": {},
   "outputs": [],
   "source": [
    "entities = class_entities.Entities(sequence, [], [], [])\n",
    "offset = 0\n",
    "\n",
    "for paragraph in paragraphs(doc):\n",
    "    #print(len(str(paragraph)))\n",
    "    disease_service.sentence_to_process(str(paragraph))\n",
    "    disease_results = disease_service.predict()\n",
    "    entities.append_new_entities(disease_results)\n",
    "    chemical_service.sentence_to_process(str(paragraph))\n",
    "    chemical_results = chemical_service.predict()\n",
    "    entities.append_new_entities(chemical_results)\n",
    "    entities.remove_non_entities()\n",
    "    entities.correct_boundaries()\n",
    "    \n",
    "    offset += len(str(paragraph))\n",
    "    disease_service.set_offset(offset)\n",
    "    chemical_service.set_offset(offset)\n",
    "\n",
    "\n",
    "disease_service.set_offset(0,restart = True)\n",
    "chemical_service.set_offset(0,restart = True)\n",
    "#print(entities.ents)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "c85c3f13-9e00-4910-970e-b317183584a4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "severe acute respiratory syndrome coronavirus\n",
      "Middle East respiratory syndrome coronavirus\n",
      "novel coronavirus\n",
      "AY278488\n",
      "None\n",
      "of pneumocytes\n",
      "[Severe acute respiratory syndrome, acute respiratory disease, coronavirus disease 2019, SARS-CoV-2 infection, acute respiratory syndrome, coronavirus disease, respiratory infections, SARS, CoV, MERS-CoV, respiratory illness, unusual viral pneumonia, coronavirus disease, coronavirus disease 2019, SARS, MERS, pneumonia, SARS, MERS, viral pneumonia, fever, cough, chest discomfort, dyspnea, pneumonia, coronavirus disease, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, pneumonia, novel, coronavirus pneumonia, COVID-19, COVID-19, pneumonia, SARS, amino acid, amino acid, zinc, Severe acute respiratory syndrome, bat, Middle East respiratory syndrome, amino acids, amino acids, amino acids, amino acid, amino acid, amino acid, amino acid, severe acute respiratory syndrome, amino acids, amino acid, amino acid, amino acid, amino acid, Ser, Lys, coronavirus infections, interstitial pneumonia, amino acid, SARS-CoV-2 infection, SARS-CoV-2 infection, respiratory distress, SARS-CoV-2, SARS-CoV-2, SARS-CoV-2, N, C, amino acid, amino acids, C, amino acids, amino acids, N, serine, SARS-CoV-2 infection, respiratory failure, Cytokine storm syndrome, acute respiratory distress syndrome, respiratory failure, acute respiratory distress syndrome, Multiple organ failure, coronavirus disease, fever, dry cough, fatigue, dyspnea, respiratory failure, ARDS, acute respiratory distress syndrome, COVID-19, alveolar damage, COVID-19, Exudative inflammation, viral interstitial pneumonia, interstitial pneumonia, COVID-19, interstitial pneumonia, Interstitial pneumonia, SARS-CoV-2 infection, respiratory disease, non, pneumonia, SARS-CoV-2, fever, fatigue, headache, haemoptysis, diarrhoea, anorexia, sore throat, chest pain, chills, nausea and vomiting, olfactory and taste disorders, dyspnoea, pneumonia, respiratory failure, septic shock, ground-glass opacity, lymphopenia, SARS, MERS, severer lymphopenia, respiratory failure, acute cardiac injury, heart failure, MERS, CoV, COVID-19, COVID-19, COVID-19, ground-glass opacities, COVID-19, COVID-19, influenza and other respiratory viral infections, COVID-19, COVID-19, pancreatitis, postoperative reflux oesophagitis, SARS-CoV-2 infection, Umifenovir, Arbidol, lopinavir, ritonavir, umifenovir, Camostat mesylate, camostat mesylate, severe acute respiratory syndrome coronavirus 2, SARS, CR3022, malaria, autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, COVID-19, cardiac arrest, COVID-19, Chloroquine, hydroxychloroquine, chloroquine, hydroxychloroquine, chloroquine, hydroxychloroquine, COVID-19, COVID-19, Allergy and Infectious Diseases, COVID-19, COVID-19, pneumonia, COVID-19, remdesivir, GS-5734, favilavir, T-705, ribavirin, lopinavir, ritonavir, lopinavir, ritonavir, Remdesivir, oxygen, remdesivir, remdesivir, oxygen, remdesivir, influenza, COVID-19, COVID-19, COVID-19, COVID-19, Favilavir, T-705, favilavir, favilavir, favilavir, favilavir, COVID-19, Lopinavir, ritonavir, lopinavir, ritonavir, lopinavir, ritonavir, COVID-19, COVID-19, Dexamethasone, dexamethasone, oxygen, arthritis, rheumatoid arthritis, cytokine release syndrome, COVID-19, pulmonary oedema, COVID-19, COVID-19, acute lung injury, allergic transfusion reactions, viral infections, SARS-CoV-2, COVID-19, SARS-CoV-2 infection, coronavirus disease, SARS, MERS, SARS-CoV-2, SARS-CoV-2, SARS-CoV-2, severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, novel coronavirus, AY278488, of pneumocytes]\n",
      "(Severe acute respiratory syndrome, acute respiratory disease, coronavirus disease 2019, SARS-CoV-2 infection, acute respiratory syndrome, coronavirus disease, respiratory infections, severe acute respiratory syndrome coronavirus, SARS, CoV, Middle East respiratory syndrome coronavirus, MERS-CoV, respiratory illness, unusual viral pneumonia, coronavirus disease, coronavirus disease 2019, SARS, MERS, pneumonia, SARS, MERS, viral pneumonia, fever, cough, chest discomfort, dyspnea, pneumonia, coronavirus disease, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, pneumonia, novel, coronavirus pneumonia, novel coronavirus, COVID-19, COVID-19, pneumonia, SARS, amino acid, amino acid, zinc, Severe acute respiratory syndrome, bat, Middle East respiratory syndrome, amino acids, amino acids, amino acids, amino acid, amino acid, amino acid, amino acid, severe acute respiratory syndrome, amino acids, AY278488, amino acid, amino acid, amino acid, amino acid, Ser, Lys, amino acid, coronavirus infections, interstitial pneumonia, SARS-CoV-2 infection, SARS-CoV-2 infection, respiratory distress, SARS-CoV-2, SARS-CoV-2, SARS-CoV-2, N, C, amino acid, amino acids, C, amino acids, amino acids, N, serine, SARS-CoV-2 infection, respiratory failure, Cytokine storm syndrome, acute respiratory distress syndrome, respiratory failure, acute respiratory distress syndrome, Multiple organ failure, coronavirus disease, fever, dry cough, fatigue, dyspnea, respiratory failure, ARDS, acute respiratory distress syndrome, COVID-19, alveolar damage, of pneumocytes, COVID-19, Exudative inflammation, viral interstitial pneumonia, interstitial pneumonia, COVID-19, interstitial pneumonia, Interstitial pneumonia, SARS-CoV-2 infection, respiratory disease, non, pneumonia, SARS-CoV-2, fever, fatigue, headache, haemoptysis, diarrhoea, anorexia, sore throat, chest pain, chills, nausea and vomiting, olfactory and taste disorders, dyspnoea, pneumonia, respiratory failure, septic shock, ground-glass opacity, lymphopenia, SARS, MERS, severer lymphopenia, respiratory failure, acute cardiac injury, heart failure, MERS, CoV, COVID-19, COVID-19, COVID-19, ground-glass opacities, COVID-19, COVID-19, Umifenovir, Arbidol, influenza and other respiratory viral infections, lopinavir, ritonavir, COVID-19, umifenovir, COVID-19, Camostat mesylate, pancreatitis, postoperative reflux oesophagitis, camostat mesylate, SARS-CoV-2 infection, severe acute respiratory syndrome coronavirus 2, SARS, CR3022, Chloroquine, hydroxychloroquine, malaria, autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, COVID-19, chloroquine, hydroxychloroquine, cardiac arrest, chloroquine, hydroxychloroquine, COVID-19, remdesivir, GS-5734, favilavir, T-705, ribavirin, lopinavir, ritonavir, lopinavir, ritonavir, Remdesivir, oxygen, COVID-19, COVID-19, Allergy and Infectious Diseases, remdesivir, COVID-19, remdesivir, COVID-19, pneumonia, oxygen, remdesivir, COVID-19, Favilavir, T-705, influenza, COVID-19, favilavir, favilavir, COVID-19, COVID-19, favilavir, favilavir, COVID-19, Lopinavir, ritonavir, lopinavir, ritonavir, COVID-19, lopinavir, ritonavir, COVID-19, Dexamethasone, dexamethasone, COVID-19, oxygen, arthritis, rheumatoid arthritis, cytokine release syndrome, COVID-19, pulmonary oedema, COVID-19, COVID-19, acute lung injury, allergic transfusion reactions, viral infections, SARS-CoV-2, COVID-19, SARS-CoV-2 infection, coronavirus disease, SARS, MERS, SARS-CoV-2, SARS-CoV-2, SARS-CoV-2)\n"
     ]
    }
   ],
   "source": [
    "postprocessing(doc,entities)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "be9cb59f-eec4-4d47-aea9-b8383954eeca",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Abstract</br>\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Severe acute respiratory syndrome\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute respiratory disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", named ‘\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronavirus disease 2019\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "’ (COVID-19), which threatens human health and public safety. In this Review, we describe the basic virology of SARS-CoV-2, including genomic characteristics and receptor use, highlighting its key difference from previously known coronaviruses. We summarize current knowledge of clinical, epidemiological and pathological features of COVID-19, as well as recent progress in animal models and antiviral treatment approaches for \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2 infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". We also discuss the potential wildlife hosts and zoonotic origin of this emerging virus in detail.</br></br>Abstract</br>In this Review, Shi and colleagues summarize the exceptional amount of research that has characterized \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute respiratory syndrome\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " coronavirus 2 (SARS-CoV-2) and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronavirus disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " 2019 (COVID-19) since this virus has swept around the globe. They discuss what we know so far about the emergence and virology of SARS-CoV-2 and the pathogenesis and treatment of COVID-19.</br></br>Introduction</br>Coronaviruses are a diverse group of viruses infecting many different animals, and they can cause mild to severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    respiratory infections\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in humans. In 2002 and 2012, respectively, two highly pathogenic coronaviruses with zoonotic origin, \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    severe acute respiratory syndrome coronavirus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CoV\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ") and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Middle East respiratory syndrome coronavirus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MERS-CoV\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "), emerged in humans and caused fatal \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    respiratory illness\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", making emerging coronaviruses a new public health concern in the twenty-first century1. At the end of 2019, a novel coronavirus designated as SARS-CoV-2 emerged in the city of Wuhan, China, and caused an outbreak of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    unusual viral pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Being highly transmissible, this novel \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronavirus disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", also known as \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronavirus disease 2019\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " (COVID-19), has spread fast all over the world2,3. It has overwhelmingly surpassed \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MERS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in terms of both the number of infected people and the spatial range of epidemic areas. The ongoing outbreak of COVID-19 has posed an extraordinary threat to global public health4,5. In this Review, we summarize the current understanding of the nature of SARS-CoV-2 and COVID-19. On the basis of recently published findings, this comprehensive Review covers the basic biology of SARS-CoV-2, including the genetic characteristics, the potential zoonotic origin and its receptor binding. Furthermore, we will discuss the clinical and epidemiological features, diagnosis of and countermeasures against COVID-19.</br></br>Emergence and spread</br>In late December 2019, several health facilities in Wuhan, in Hubei province in China, reported clusters of patients with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " of unknown cause6. Similarly to patients with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MERS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", these patients showed symptoms of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    viral pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", including \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fever\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cough\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    chest discomfort\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", and in severe cases \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dyspnea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and bilateral lung infiltration6,7. Among the first 27 documented hospitalized patients, most cases were epidemiologically linked to Huanan Seafood Wholesale Market, a wet market located in downtown Wuhan, which sells not only seafood but also live animals, including poultry and wildlife4,8. According to a retrospective study, the onset of the first known case dates back to 8 December 2019 (ref.9). On 31 December, Wuhan Municipal Health Commission notified the public of a \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " outbreak of unidentified cause and informed the World Health Organization (WHO)9 (Fig. 1).</br></br>Fig. 1View larger versionFig. 1. Timeline of the key events of the COVID-19 outbreak.The first recorded cases were reported in December 2019 in Wuhan, China. Over the course of the following 10 months, more than 30 million cases have been confirmed worldwide. COVID-19, \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronavirus disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " 2019; ICTV, International Committee on Taxonomy of Viruses; PHEIC, public health emergency of international concern; \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    severe acute respiratory syndrome coronavirus 2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "; WHO, World Health Organization.</br></br>By metagenomic RNA sequencing and virus isolation from bronchoalveolar lavage fluid samples from patients with severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", independent teams of Chinese scientists identified that the causative agent of this emerging disease is a betacoronavirus that had never been seen before6,10,11. On 9 January 2020, the result of this etiological identification was publicly announced (Fig. 1). The first genome sequence of the novel coronavirus was published on the Virological website on 10 January, and more nearly complete genome sequences determined by different research institutes were then released via the GISAID database on 12 January7. Later, more patients with no history of exposure to Huanan Seafood Wholesale Market were identified. Several familial clusters of infection were reported, and nosocomial infection also occurred in health-care facilities. All these cases provided clear evidence for human-to-human transmission of the new virus4,12–14. As the outbreak coincided with the approach of the lunar New Year, travel between cities before the festival facilitated virus transmission in China. This \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    novel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronavirus pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " soon spread to other cities in Hubei province and to other parts of China. Within 1 month, it had spread massively to all 34 provinces of China. The number of confirmed cases suddenly increased, with thousands of new cases diagnosed daily during late January15. On 30 January, the WHO declared the \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    novel coronavirus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " outbreak a public health emergency of international concern16. On 11 February, the International Committee on Taxonomy of Viruses named the novel coronavirus ‘SARS-CoV-2’, and the WHO named the disease ‘COVID-19’ (ref.17).</br></br>The outbreak of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in China reached an epidemic peak in February. According to the National Health Commission of China, the total number of cases continued to rise sharply in early February at an average rate of more than 3,000 newly confirmed cases per day. To control \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", China implemented unprecedentedly strict public health measures. The city of Wuhan was shut down on 23 January, and all travel and transportation connecting the city was blocked. In the following couple of weeks, all outdoor activities and gatherings were restricted, and public facilities were closed in most cities as well as in countryside18. Owing to these measures, the daily number of new cases in China started to decrease steadily19.</br></br>However, despite the declining trend in China, the international spread of COVID-19 accelerated from late February. Large clusters of infection have been reported from an increasing number of countries18. The high transmission efficiency of SARS-CoV-2 and the abundance of international travel enabled rapid worldwide spread of COVID-19. On 11 March 2020, the WHO officially characterized the global COVID-19 outbreak as a pandemic20. Since March, while COVID-19 in China has become effectively controlled, the case numbers in Europe, the USA and other regions have jumped sharply. According to the COVID-19 dashboard of the Center for System Science and Engineering at Johns Hopkins University, as of 11 August 2020, 216 countries and regions from all six continents had reported more than 20 million cases of COVID-19, and more than 733,000 patients had died21. High mortality occurred especially when health-care resources were overwhelmed. The USA is the country with the largest number of cases so far.</br></br>Although genetic evidence suggests that SARS-CoV-2 is a natural virus that likely originated in animals, there is no conclusion yet about when and where the virus first entered humans. As some of the first reported cases in Wuhan had no epidemiological link to the seafood market22, it has been suggested that the market may not be the initial source of human infection with SARS-CoV-2. One study from France detected SARS-CoV-2 by PCR in a stored sample from a patient who had \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " at the end of 2019, suggesting \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "-CoV-2 might have spread there much earlier than the generally known starting time of the outbreak in France23. However, this individual early report cannot give a solid answer to the origin of SARS-CoV-2 and contamination, and thus a false positive result cannot be excluded. To address this highly controversial issue, further retrospective investigations involving a larger number of banked samples from patients, animals and environments need to be conducted worldwide with well-validated assays.</br></br>Genomics, phylogeny and taxonomy</br>As a novel betacoronavirus, SARS-CoV-2 shares 79% genome sequence identity with SARS-CoV and 50% with MERS-CoV24. Its genome organization is shared with other betacoronaviruses. The six functional open reading frames (ORFs) are arranged in order from 5′ to 3′: replicase (ORF1a/ORF1b), spike (S), envelope (E), membrane (M) and nucleocapsid (N). In addition, seven putative ORFs encoding accessory proteins are interspersed between the structural genes25. Most of the proteins encoded by SARS-CoV-2 have a similar length to the corresponding proteins in SARS-CoV. Of the four structural genes, SARS-CoV-2 shares more than 90% \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " identity with SARS-CoV except for the S gene, which diverges11,24. The replicase gene covers two thirds of the 5′ genome, and encodes a large polyprotein (pp1ab),which is proteolytically cleaved into 16 non-structural proteins that are involved in transcription and virus replication. Most of these SARS-CoV-2 non-structural proteins have greater than 85% \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " sequence identity with SARS-CoV25.</br></br>The phylogenetic analysis for the whole genome shows that SARS-CoV-2 is clustered with SARS-CoV and SARS-related coronaviruses (SARSr-CoVs) found in bats, placing it in the subgenus Sarbecovirus of the genus Betacoronavirus. Within this clade, SARS-CoV-2 is grouped in a distinct lineage together with four horseshoe bat coronavirus isolates (RaTG13, RmYN02, ZC45 and ZXC21) as well as novel coronaviruses recently identified in pangolins, which group parallel to SARS-CoV and other SARSr-CoVs (Fig. 2). Using sequences of five conserved replicative domains in pp1ab (3C-like protease (3CLpro), nidovirus RNA-dependent RNA polymerase (RdRp)-associated nucleotidyltransferase (NiRAN), RdRp, \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    zinc\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "-binding domain (ZBD) and HEL1), the Coronaviridae Study Group of the International Committee on Taxonomy of Viruses estimated the pairwise patristic distances between SARS-CoV-2 and known coronaviruses, and assigned SARS-CoV-2 to the existing species SARSr-CoV17. Although phylogenetically related, SARS-CoV-2 is distinct from all other coronaviruses from bats and pangolins in this species.</br></br>Fig. 2View larger versionFig. 2. Phylogenetic tree of the full-length genome sequences of SARS-CoV-2, SARSr-CoVs and other betacoronaviruses.The construction was performed by the neighbour joining method with use of the program MEGA6 with bootstrap values being calculated from 1,000 trees. \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Severe acute respiratory syndrome\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " coronavirus 2 (SARS-CoV-2) clusters with closely related viruses in bats and pangolins and together with SARS-CoV and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bat\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " SARS-related coronaviruses (SARSr-CoVs) forms the sarbecoviruses. The sequences were downloaded from the GISAID database and GenBank. MERS-CoV, \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Middle East respiratory syndrome\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " coronavirus.</br></br>The SARS-CoV-2 S protein has a full size of 1,273 \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acids\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", longer than that of SARS-CoV (1,255 \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acids\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ") and known bat SARSr-CoVs (1,245–1,269 \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acids\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "). It is distinct from the S proteins of most members in the subgenus Sarbecovirus, sharing \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " sequence similarities of 76.7–77.0% with SARS-CoVs from civets and humans, 75–97.7% with bat coronaviruses in the same subgenus and 90.7–92.6% with pangolin coronaviruses11. In the receptor-binding domain (RBD) of S protein, the \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " similarity between SARS-CoV-2 and SARS-CoV is only 73%. Another specific genomic feature of SARS-CoV-2 is the insertion of four \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " residues (PRRA) at the junction of subunits S1 and S2 of the S protein26 (Fig. 3a). This insertion generates a polybasic cleavage site (RRAR), which enables effective cleavage by furin and other proteases27. Such an S1–S2 cleavage site is not observed in all related viruses belonging to the subgenus Sarbecovirus, except for a similar three \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " insertion (PAA) in RmYN02, a bat-derived coronavirus newly reported from Rhinolophus malayanus in China28 (Fig. 3a). Although the insertion in RmYN02 does not functionally represent a polybasic cleavage site, it provides support for the notion that this characteristic, initially considered unique to SARS-CoV-2, has been acquired naturally28. A structural study suggested that the furin-cleavage site can reduce the stability of SARS-CoV-2 S protein and facilitate the conformational adaption that is required for the binding of the RBD to its receptor29. Whether the higher transmissibility of SARS-CoV-2 compared with SARS-CoV is a gain of function associated with acquisition of the furin-like cleavage site is yet to be demonstrated26.</br></br>Fig. 3View larger versionFig. 3. Key differences in the spike protein of SARS-CoV-2 and related coronaviruses.a | Schematic diagram of the spike (S) protein of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    severe acute respiratory syndrome\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " coronavirus (SARS-CoV) and SARS-CoV-2. The residue numbers of each region correspond to their positions in the S proteins of SARS-CoV and SARS-CoV-2. The dark blue blocks represent insertions in the S protein. The insertions at \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acids\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 675–691 of the SARS-CoV-2 S protein are shown in an enlargement at the bottom right and aligned with those of other coronaviruses in the same region. b | Alignment of the receptor-binding domain (RBD) in SARS-CoV-2, SARS-CoV BJ01, RaTG13, pangolin coronavirus reported from Guangdong, China (GD pangolin), pangolin coronavirus reported from Guangxi, China (GX pangolin) and bat SARS-related coronavirus (SARSr-CoV) WIV1. The receptor-binding motif (RBM) is shown in purple, and the five key residues that contact angiotensin-converting enzyme 2 (ACE2) directly are highlighted in green. c | Five critical residues in the RBD of SARS-CoV-2 and other viruses. d | Comparison of the structure of SARS-CoV-2 and SARS-CoV RBD complexed with human ACE2 (hACE2); SARS-CoV-2 RBM in purple, SARS-CoV RBM in yellow and hACE2 in green). Five critical residues that are involved in the RBM–ACE2 binding are shown. The Protein Data Bank codes are 2AJF for SARS-CoV RBD–hACE2 and 6VW1 for SARS-CoV-2 RBD–hACE2. The GenBank entries are \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AY278488\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " for SARS-CoV BJ01, MN996532 for the bat SARSr-CoV RaTG13, MT121216 and MT072864 for the GD pangolin and GX pangolin coronaviruses, respectively, and KF367457 for the bat SARSr-CoV WIV1. CP, cytoplasmic domain; FP, fusion peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; NTD, N-terminal domain; SP, signal peptide; TM, transmembrane domain. Parts a and b adapted from ref.26, Springer Nature Limited.</br></br>An additional distinction is the accessory gene orf8 of SARS-CoV-2, which encodes a novel protein showing only 40% \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " identity to ORF8 of SARS-CoV. Unlike in SARS-CoV, this new ORF8 protein does not contain a motif that triggers intracellular stress pathways25. Notably, a SARS-CoV-2 variant with a 382-nucleotide deletion covering the whole of ORF8 has been discovered in a number of patients in Singapore, which resembles the 29- or 415-nucleotide deletions in the ORF8 region observed in human SARS-CoV variants from the late phase of the 2002–2003 outbreak30. Such ORF8 deletion may be indicative of human adaptation after cross-species transmission from an animal host.</br></br>To assess the genetic variation of different SARS-CoV-2 strains, the 2019 Novel Coronavirus Resource of China National Center for Bioinformation aligned 77,801 genome sequences of SARS-CoV-2 detected globally and identified a total of 15,018 mutations, including 14,824 single-nucleotide polymorphisms (BIGD)31. In the S protein, four \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " alterations, V483A, L455I, F456V and G476S, are located near the binding interface in the RBD, but their effects on binding to the host receptor are unknown. The alteration D614G in the S1 subunit was found far more frequently than other S variant sites, and it is the marker of a major subclade of SARS-CoV-2 (clade G). Since March 2020, SARS-CoV-2 variants with G614 in the S protein have replaced the original D614 variants and become the dominant form circulating globally. Compared with the D614 variant, higher viral loads were found in patients infected with the G614 variant, but clinical data suggested no significant link between the D614G alteration and disease severity32. Pseudotyped viruses carrying the S protein with G614 generated higher infectious titres than viruses carrying the S protein with D614, suggesting the alteration may have increased the infectivity of SARS-CoV-2 (ref.32). However, the results of in vitro experiments based on pseudovirus models may not exactly reflect natural infection. This preliminary finding should be validated by more studies using wild-type SARS-CoV-2 variants to infect different target cells and animal models. Whether this \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " change enhanced virus transmissibility is also to be determined. Another marker mutation for SARS-CoV-2 evolution is the single-nucleotide polymorphism at nucleotide position 28,144, which results in \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " substitution of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ser\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lys\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " at residue 84 of the ORF8 protein. Those variants with this mutation make up a single subclade labelled as ‘clade S’33,34. Currently, however, the available sequence data are not sufficient to interpret the early global transmission history of the virus, and travel patterns, founder effects and public health measures also strongly influence the spread of particular lineages, irrespective of potential biological differences between different virus variants.</br></br>Animal host and spillover</br>Bats are important natural hosts of alphacoronaviruses and betacoronaviruses. The closest relative to SARS-CoV-2 known to date is a bat coronavirus detected in Rhinolophus affinis from Yunnan province, China, named ‘RaTG13’, whose full-length genome sequence is 96.2% identical to that of SARS-CoV-2 (ref.11). This bat virus shares more than 90% sequence identity with SARS-CoV-2 in all ORFs throughout the genome, including the highly variable S and ORF8 (ref.11). Phylogenetic analysis confirms that SARS-CoV-2 closely clusters with RaTG13 (Fig. 2). The high genetic similarity between SARS-CoV-2 and RaTG13 supports the hypothesis that SARS-CoV-2 likely originated from bats35. Another related coronavirus has been reported more recently in a Rhinolophus malayanus bat sampled in Yunnan. This novel bat virus, denoted ‘RmYN02’, is 93.3% identical to SARS-CoV-2 across the genome. In the long 1ab gene, it exhibits 97.2% identity to SARS-CoV-2, which is even higher than for RaTG13 (ref.28). In addition to RaTG13 and RmYN02, phylogenetic analysis shows that bat coronaviruses ZC45 and ZXC21 previously detected in Rhinolophus pusillus bats from eastern China also fall into the SARS-CoV-2 lineage of the subgenus Sarbecovirus36 (Fig. 2). The discovery of diverse bat coronaviruses closely related to SARS-CoV-2 suggests that bats are possible reservoirs of SARS-CoV-2 (ref.37). Nevertheless, on the basis of current findings, the divergence between SARS-CoV-2 and related bat coronaviruses likely represents more than 20 years of sequence evolution, suggesting that these bat coronaviruses can be regarded only as the likely evolutionary precursor of SARS-CoV-2 but not as the direct progenitor of SARS-CoV-2 (ref.38).</br></br>Beyond bats, pangolins are another wildlife host probably linked with SARS-CoV-2. Multiple SARS-CoV-2-related viruses have been identified in tissues of Malayan pangolins smuggled from Southeast Asia into southern China from 2017 to 2019. These viruses from pangolins independently seized by Guangxi and Guangdong provincial customs belong to two distinct sublineages39–41. The Guangdong strains, which were isolated or sequenced by different research groups from smuggled pangolins, have 99.8% sequence identity with each other41. They are very closely related to SARS-CoV-2, exhibiting 92.4% sequence similarity. Notably, the RBD of Guangdong pangolin coronaviruses is highly similar to that of SARS-CoV-2. The receptor-binding motif (RBM; which is part of the RBD) of these viruses has only one \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " variation from SARS-CoV-2, and it is identical to that of SARS-CoV-2 in all five critical residues for receptor binding40 (Fig. 3b). In comparison with the Guangdong strains, pangolin coronaviruses reported from Guangxi are less similar to SARS-CoV-2, with 85.5% genome sequence identity39. The repeated occurrence of SARS-CoV-2-related \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronavirus infections\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in pangolins from different smuggling events suggests that these animals are possible hosts of the viruses. However, unlike bats, which carry coronaviruses healthily, the infected pangolins showed clinical signs and histopathological changes, including \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    interstitial pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and inflammatory cell infiltration in diverse organs40. These abnormalities suggest that pangolins are unlikely to be the reservoir of these coronaviruses but more likely acquired the viruses after spillover from the natural hosts.</br></br>An intermediate host usually plays an important role in the outbreak of bat-derived emerging coronaviruses; for example, palm civets for SARS-CoV and dromedary camels for MERS-CoV. The virus strains carried by these two intermediate hosts were almost genetically identical to the corresponding viruses in humans (more than 99% genome sequence identity)1. Despise an RBD that is virtually identical to that of SARS-CoV-2, the pangolin coronaviruses known to date have no more than 92% genome identity with SARS-CoV-2 (ref.42). The available data are insufficient to interpret pangolins as the intermediate host of SARS-CoV-2. So far, no evidence has shown that pangolins were directly involved in the emergence of SARS-CoV-2.</br></br>Currently, our knowledge on the animal origin of SARS-CoV-2 remains incomplete to a large part. The reservoir hosts of the virus have not been clearly proven. It is unknown whether SARS-CoV-2 was transmitted to humans through an intermediate host and which animals may act as its intermediate host. Detection of RaTG13, RmYN02 and pangolin coronaviruses implies that diverse coronaviruses similar to SARS-CoV-2 are circulating in wildlife. In addition, as previous studies showed recombination as the potential origin of some sarbecoviruses such as SARS-CoV, it cannot be excluded that viral RNA recombination among different related coronaviruses was involved in the evolution of SARS-CoV-2. Extensive surveillance of SARS-CoV-2-related viruses in China, Southeast Asia and other regions targeting bats, wild and captured pangolins and other wildlife species will help us to better understand the zoonotic origin of SARS-CoV-2.</br></br>Besides wildlife, researchers investigated the susceptibility of domesticated and laboratory animals to \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2 infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". The study demonstrated experimentally that SARS-CoV-2 replicates efficiently in cats and in the upper respiratory tract of ferrets, whereas dogs, pigs, chickens and ducks were not susceptible to SARS-CoV-2 (ref.43). The susceptibility of minks was documented by a report from the Netherlands on an outbreak of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2 infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in farmed minks. Although the symptoms in most infected minks were mild, some developed severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    respiratory distress\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and died of interstitial pneumonia44. Both virological and serological testing found evidence for natural \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " infection in two dogs from households with human cases of COVID-19 in Hong Kong, but the dogs appeared asymptomatic45. Another serological study detected SARS-CoV-2 neutralizing antibodies in cat serum samples collected in Wuhan after the COVID-19 outbreak, providing evidence for \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " infection in cat populations in Wuhan, although the potential of SARS-CoV-2 transmission from cats to humans is currently uncertain46.</br></br>Receptor use and pathogenesis</br>SARS-CoV-2 uses the same receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2)11,47. Besides human ACE2 (hACE2), SARS-CoV-2 also recognizes ACE2 from pig, ferret, rhesus monkey, civet, cat, pangolin, rabbit and dog11,43,48,49. The broad receptor usage of SARS-CoV-2 implies that it may have a wide host range, and the varied efficiency of ACE2 usage in different animals may indicate their different susceptibilities to \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " infection. The S1 subunit of a coronavirus is further divided into two functional domains, an \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    N\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "-terminal domain and a \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    C\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "-terminal domain. Structural and biochemical analyses identified a 211 \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " region (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acids\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 319–529) at the S1 \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    C\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "-terminal domain of SARS-CoV-2 as the RBD, which has a key role in virus entry and is the target of neutralizing antibodies50,51 (Fig. 3a). The RBM mediates contact with the ACE2 receptor (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acids\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 437–507 of SARS-CoV-2 S protein), and this region in SARS-CoV-2 differs from that in SARS-CoV in the five residues critical for ACE2 binding, namely Y455L, L486F, N493Q, D494S and T501N52 (Fig. 3b,c). Owing to these residue changes, interaction of SARS-CoV-2 with its receptor stabilizes the two virus-binding hotspots on the surface of hACE2 (ref.50) (Fig. 3d). Moreover, a four-residue motif in the RBM of SARS-CoV-2 (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amino acids\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 482–485: G-V-E-G) results in a more compact conformation of its hACE2-binding ridge than in SARS-CoV and enables better contact with the \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    N\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "-terminal helix of hACE2 (ref.50). Biochemical data confirmed that the structural features of the SARS-CoV-2 RBD has strengthened its hACE2 binding affinity compared with that of SARS-CoV50,52,53.</br></br>Similarly to other coronaviruses, SARS-CoV-2 needs proteolytic processing of the S protein to activate the endocytic route. It has been shown that host proteases participate in the cleavage of the S protein and activate the entry of SARS-CoV-2, including transmembrane protease \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    serine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " protease 2 (TMPRSS2), cathepsin L and furin47,54,55. Single-cell RNA sequencing data showed that TMPRSS2 is highly expressed in several tissues and body sites and is co-expressed with ACE2 in nasal epithelial cells, lungs and bronchial branches, which explains some of the tissue tropism of SARS-CoV-2 (refs56,57). SARS-CoV-2 pseudovirus entry assays revealed that TMPRSS2 and cathepsin L have cumulative effects with furin on activating virus entry55. Analysis of the cryo-electron microscopy structure of SARS-CoV-2 S protein revealed that its RBD is mostly in the lying-down state, whereas the SARS-CoV S protein assumes equally standing-up and lying-down conformational states50,51,58,59. A lying-down conformation of the SARS-CoV-2 S protein may not be in favour of receptor binding but is helpful for immune evasion55.</br></br>The pathogenesis of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2 infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in humans manifests itself as mild symptoms to severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    respiratory failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". On binding to epithelial cells in the respiratory tract, SARS-CoV-2 starts replicating and migrating down to the airways and enters alveolar epithelial cells in the lungs. The rapid replication of SARS-CoV-2 in the lungs may trigger a strong immune response. \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cytokine storm syndrome\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " causes \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute respiratory distress syndrome\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    respiratory failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", which is considered the main cause of death in patients with COVID-19 (refs60,61). Patients of older age (&gt;60 years) and with serious pre-existing diseases have a greater risk of developing \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute respiratory distress syndrome\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and death62–64 (Fig. 4). \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Multiple organ failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " has also been reported in some COVID-19 cases9,13,65.</br></br>Fig. 4View larger versionFig. 4. Clinical features of COVID-19.Typical symptoms of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronavirus disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " 2019 (COVID-19) are \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fever\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dry cough\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and in severer cases \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dyspnea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Many infections, in particular in children and young adults, are asymptomatic, whereas older people and/or people with co-morbidities are at higher risk of severe disease, \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    respiratory failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and death. The incubation period is ~5 days, severe disease usually develops ~8 days after symptom onset and critical disease and death occur at ~16 days. \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ARDS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute respiratory distress syndrome\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "; ICU, intensive care unit.</br></br>Histopathological changes in patients with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " occur mainly in the lungs. Histopathology analyses showed bilateral diffused \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    alveolar damage\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", hyaline membrane formation, desquamation \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    of pneumocytes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and fibrin deposits in lungs of patients with severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Exudative inflammation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " was also shown in some cases. Immunohistochemistry assays detected SARS-CoV-2 antigen in the upper airway, bronchiolar epithelium and submucosal gland epithelium, as well as in type I and type II pneumocytes, alveolar macrophages and hyaline membranes in the lungs13,60,66,67.</br></br>Animal models used for studying SARS-CoV-2 infection pathogenesis include non-human primates (rhesus macaques, cynomolgus monkeys, marmosets and African green monkeys), mice (wild-type mice (with mouse-adapted virus) and human ACE2-transgenic or human ACE2-knock-in mice), ferrets and golden hamsters43,48,68–74. In non-human primate animal models, most species display clinical features similar to those of patients with COVID-19, including virus shedding, virus replication and host responses to SARS-CoV-2 infection69,72,73. For example, in the rhesus macaque model, high viral loads were detected in the upper and lower respiratory tracts. Acute \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    viral interstitial pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and humoral and cellular immune responses were observed48,75. Moreover, prolonged virus shedding peaked early in the course of infection in asymptomatic macaques69, and old monkeys showed severer \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    interstitial pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " than young monkeys76, which is similar to what is seen in patients with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". In human ACE2-transgenic mice infected with SARS-CoV-2, typical \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    interstitial pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " was present, and viral antigens were observed mainly in the bronchial epithelial cells, macrophages and alveolar epithelia. Some human ACE2-transgenic mice even died after infection70,71. In wide-type mice, a SARS-CoV-2 mouse-adapted strain with the N501Y alteration in the RBD of the S protein was generated at passage 6. \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Interstitial pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and inflammatory responses were found in both young and aged mice after infection with the mouse-adapted strain74. Golden hamsters also showed typical symptoms after being infected with SARS-CoV-2 (ref.77). In other animal models, including cats and ferrets, SARS-CoV-2 could efficiently replicate in the upper respiratory tract but did not induce severe clinical symptoms43,78. As transmission by direct contact and air was observed in infected ferrets and hamsters, these animals could be used to model different transmission modes of COVID-19 (refs77–79). Animal models offer important information for understanding the pathogenesis of SARS-CoV-2 infection and the transmission dynamics of SARS-CoV-2, and are important to evaluate the efficacy of antiviral therapeutics and vaccines.</br></br>Clinical and epidemiological features</br>It appears that all ages of the population are susceptible to \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2 infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", and the median age of infection is around 50 years9,13,60,80,81. However, clinical manifestations differ with age. In general, older men (&gt;60 years old) with co-morbidities are more likely to develop severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    respiratory disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " that requires hospitalization or even die, whereas most young people and children have only mild diseases (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    non\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " or mild pneumonia) or are asymptomatic9,81,82. Notably, the risk of disease was not higher for pregnant women. However, evidence of transplacental transmission of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " from an infected mother to a neonate was reported, although it was an isolated case83,84. On infection, the most common symptoms are \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fever\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and dry cough13,60,80,81. Less common symptoms include sputum production, \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    headache\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    haemoptysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    diarrhoea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    anorexia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sore throat\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    chest pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    chills\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nausea and vomiting\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in studies of patients in China13,60,80,81. Self-reported \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    olfactory and taste disorders\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " were also reported by patients in Italy85. Most people showed signs of diseases after an incubation period of 1–14 days (most commonly around 5 days), and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dyspnoea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " developed within a median time of 8 days from illness onset9.</br></br>In a report of 72,314 cases in China, 81% of the cases were classified as mild, 14% were severe cases that required ventilation in an intensive care unit (ICU) and a 5% were critical (that is, the patients had \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    respiratory failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    septic shock\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and/or multiple organ dysfunction or failure)9,86. On admission, \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ground-glass opacity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " was the most common radiologic finding on chest computed tomography (CT)13,60,80,81. Most patients also developed marked \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lymphopenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", similar to what was observed in patients with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MERS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", and non-survivors developed \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    severer lymphopenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " over time13,60,80,81. Compared with non-ICU patients, ICU patients had higher levels of plasma cytokines, which suggests an immunopathological process caused by a cytokine storm60,86,87. In this cohort of patient, around 2.3% people died within a median time of 16 days from disease onset9,86. Men older than 68 years had a higher risk of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    respiratory failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute cardiac injury\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    heart failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " that led to death, regardless of a history of cardiovascular disease86 (Fig. 4). Most patients recovered enough to be released from hospital in 2 weeks9,80 (Fig. 4).</br></br>Early transmission of SARS-CoV-2 in Wuhan in December 2019 was initially linked to the Huanan Seafood Wholesale Market, and it was suggested as the source of the outbreak9,22,60. However, community transmission might have happened before that88. Later, ongoing human-to-human transmission propagated the outbreak9. It is generally accepted that SARS-CoV-2 is more transmissible than SARS-CoV and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MERS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "-CoV; however, determination of an accurate reproduction number (R0) for COVID-19 is not possible yet, as many asymptomatic infections cannot be accurately accounted for at this stage89. An estimated R0 of 2.5 (ranging from 1.8 to 3.6) has been proposed for SARS-CoV-2 recently, compared with 2.0–3.0 for SARS-CoV90. Notably, most of the SARS-CoV-2 human-to-human transmission early in China occurred in family clusters, and in other countries large outbreaks also happened in other settings, such as migrant worker communities, slaughterhouses and meat packing plants, indicating the necessity of isolating infected people9,12,91–93. Nosocomial transmission was not the main source of transmission in China because of the implementation of infection control measures in clinical settings9. By contrast, a high risk of nosocomial transmission was reported in some other areas. For example, a cohort study in London revealed 44% of the frontline health-care workers from a hospital were infected with SARS-CoV-2 (ref.94).</br></br>The high transmissibility of SARS-CoV-2 may be attributed to the unique virological features of SARS-CoV-2. Transmission of SARS-\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CoV\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " occurred mainly after illness onset and peaked following disease severity95. However, the SARS-CoV-2 viral load in upper respiratory tract samples was already highest during the first week of symptoms, and thus the risk of pharyngeal virus shedding was very high at the beginning of infection96,97. It was postulated that undocumented infections might account for 79% of documented cases owing to the high transmissibility of the virus during mild disease or the asymptomatic period89. A patient with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " spreads viruses in liquid droplets during speech. However, smaller and much more numerous particles known as aerosol particles can also be visualized, which could linger in the air for a long time and then penetrate deep into the lungs when inhaled by someone else98–100. Airborne transmission was also observed in the ferret experiments mentioned above. SARS-CoV-2-infected ferrets shed viruses in nasal washes, saliva, urine and faeces for up to 8 days after infection, and a few naive ferrets with only indirect contact were positive for viral RNA, suggesting airborne transmission78. In addition, transmission of the virus through the ocular surface and prolonged presence of SARS-CoV-2 viral RNA in faecal samples were also documented101,102. Coronaviruses can persist on inanimate surfaces for days, which could also be the case for SARS-CoV-2 and could pose a prolonged risk of infection103. These findings explain the rapid geographic spread of COVID-19, and public health interventions to reduce transmission will provide benefit to mitigate the epidemic, as has proved successful in China and several other countries, such as South Korea89,104,105.</br></br>Diagnosis</br>Early diagnosis is crucial for controlling the spread of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Molecular detection of SARS-CoV-2 nucleic acid is the gold standard. Many viral nucleic acid detection kits targeting ORF1b (including RdRp), N, E or S genes are commercially available11,106–109. The detection time ranges from several minutes to hours depending on the technology106,107,109–111. The molecular detection can be affected by many factors. Although SARS-CoV-2 has been detected from a variety of respiratory sources, including throat swabs, posterior oropharyngeal saliva, nasopharyngeal swabs, sputum and bronchial fluid, the viral load is higher in lower respiratory tract samples11,96,112–115. In addition, viral nucleic acid was also found in samples from the intestinal tract or blood even when respiratory samples were negative116. Lastly, viral load may already drop from its peak level on disease onset96,97. Accordingly, false negatives can be common when oral swabs and used, and so multiple detection methods should be adopted to confirm a COVID-19 diagnosis117,118. Other detection methods were therefore used to overcome this problem. Chest CT was used to quickly identify a patient when the capacity of molecular detection was overloaded in Wuhan. Patients with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " showed typical features on initial CT, including bilateral multilobar \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ground-glass opacities\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with a peripheral or posterior distribution118,119. Thus, it has been suggested that CT scanning combined with repeated swab tests should be used for individuals with high clinical suspicion of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " but who test negative in initial nucleic acid screening118. Finally, SARS-CoV-2 serological tests detecting antibodies to N or S protein could complement molecular diagnosis, particularly in late phases after disease onset or for retrospective studies116,120,121. However, the extent and duration of immune responses are still unclear, and available serological tests differ in their sensitivity and specificity, all of which need to be taken into account when one is deciding on serological tests and interpreting their results or potentially in the future test for T cell responses.</br></br>Therapeutics</br>To date, there are no generally proven effective therapies for COVID-19 or antivirals against SARS-CoV-2, although some treatments have shown some benefits in certain subpopulations of patients or for certain end points (see later). Researchers and manufacturers are conducting large-scale clinical trials to evaluate various therapies for COVID-19. As of 2 October 2020, there were about 405 therapeutic drugs in development for COVID-19, and nearly 318 in human clinical trials (COVID-19 vaccine and therapeutics tracker). In the following sections, we summarize potential therapeutics against SARS-CoV-2 on the basis of published clinical data and experience.</br></br>Inhibition of virus entry</br>SARS-CoV-2 uses ACE2 as the receptor and human proteases as entry activators; subsequently it fuses the viral membrane with the cell membrane and achieves invasion. Thus, drugs that interfere with entry may be a potential treatment for \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Umifenovir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Arbidol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ") is a drug approved in Russia and China for the treatment of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    influenza and other respiratory viral infections\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". It can target the interaction between the S protein and ACE2 and inhibit membrane fusion (Fig. 5). In vitro experiments showed that it has activity against SARS-CoV-2, and current clinical data revealed it may be more effective than \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lopinavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ritonavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " in treating \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " (refs122,123). However, other clinical studies showed \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    umifenovir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " might not improve the prognosis of or accelerate SARS-CoV-2 clearance in patients with mild to moderate \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " (refs124,125). Yet some ongoing clinical trials are evaluating its efficacy for COVID-19 treatment. \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Camostat mesylate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " is approved in Japan for the treatment of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pancreatitis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    postoperative reflux oesophagitis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Previous studies showed that it can prevent SARS-CoV from entering cells by blocking TMPRSS2 activity and protect mice from lethal infection with SARS-CoV in a pathogenic mouse model (wild-type mice infected with a mouse-adapted SARS-CoV strain)126,127. Recently, a study revealed that \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    camostat mesylate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " blocks the entry of SARS-CoV-2 into human lung cells47. Thus, it can be a potential antiviral drug against \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2 infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", although so far there are not sufficient clinical data to support its efficacy.</br></br>Fig. 5View larger versionFig. 5. SARS-CoV-2 replication and potential therapeutic targets.Potential antivirals target the different steps of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    severe acute respiratory syndrome coronavirus 2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "-CoV-2) replication, ranging from receptor binding, entry and fusion to replication. Furthermore, immunoglobulin-based and immunomodulatory drugs are potential therapeutics as well. Note that robust data on clinical efficacy are lacking for most of these treatments so far. 3CLpro, 3C-like protease; ACE2, angiotensin-converting enzyme 2; \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CR3022\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", a SARS-CoV-specific human monoclonal antibody; E, envelope protein; EK1C4, lipopeptide derived from EK1 which is a pan-coronavirus fusion inhibitor targeting the HR1 domain of the spike protein; ER, endoplasmic reticulum; gRNA, genomic RNA; HR2P, heptad repeat 2-derived peptides of SARS-CoV-2 spike protein; IL-6, interleukin-6; ISG, interferon-stimulated gene; M, membrane protein; RdRp, RNA-dependent RNA polymerases; sgRNA, subgenomic RNA; S, spike protein; TMPRSS2, transmembrane protease serine protease 2.</br></br>\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chloroquine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hydroxychloroquine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " are other potential but controversial drugs that interfere with the entry of SARS-CoV-2. They have been used in the prevention and treatment of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    malaria\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    autoimmune diseases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", including \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    systemic lupus erythematosus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rheumatoid arthritis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". They can inhibit the glycosylation of cellular receptors and interfere with virus–host receptor binding, as well as increase the endosomal pH and inhibit membrane fusion. Currently, no scientific consensus has been reached for their efficacy in the treatment of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Some studies showed they can inhibit SARS-CoV-2 infection in vitro, but the clinical data are insufficient128,129. Two clinical studies indicated no association with death rates in patients receiving \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    chloroquine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hydroxychloroquine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " compared with those not receiving the drug and even suggest it may increase the risk of dying as a higher risk of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiac arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " was found in the treated patients130,131. On 15 June 2020, owing to the side effects observed in clinical trials, the US Food and Drug Administration (FDA) revoked the emergency use authorization for \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    chloroquine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hydroxychloroquine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " for the treatment of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Another potential therapeutic strategy is to block binding of the S protein to ACE2 through soluble recombinant hACE2, specific monoclonal antibodies or fusion inhibitors that target the SARS-CoV-2 S protein132–134 (Fig. 5). The safety and efficacy of these strategies need to be assessed in future clinical trials.</br></br>Inhibition of virus replication</br>Replication inhibitors include \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    remdesivir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GS-5734\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "), \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    favilavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T-705\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "), \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ribavirin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lopinavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ritonavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". Except for \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lopinavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ritonavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", which inhibit 3CLpro, the other three all target RdRp128,135 (Fig. 5). \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Remdesivir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " has shown activity against SARS-CoV-2 in vitro and in vivo128,136. A clinical study revealed a lower need for \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    oxygen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " support in patients with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " (ref.137). Preliminary results of the Adaptive \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " Treatment Trial (ACTT) clinical trial by the National Institute of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Allergy and Infectious Diseases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " (NIAID) reported that \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    remdesivir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " can shorten the recovery time in hospitalized adults with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " by a couple days compared with placebo, but the difference in mortality was not statistically significant138. The FDA has issued an emergency use authorization for \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    remdesivir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " for the treatment of hospitalized patients with severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". It is also the first approved option by the European Union for treatment of adults and adolescents with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " requiring supplemental \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    oxygen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". Several international phase III clinical trials are continuing to evaluate the safety and efficacy of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    remdesivir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " for the treatment of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br></br>\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Favilavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T-705\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "), which is an antiviral drug developed in Japan to treat \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    influenza\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", has been approved in China, Russia and India for the treatment of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". A clinical study in China showed that \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    favilavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " significantly reduced the signs of improved disease signs on chest imaging and shortened the time to viral clearance139. A preliminary report in Japan showed rates of clinical improvement of 73.8% and 87.8% from the start of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    favilavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " therapy in patients with mild \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " at 7 and 14 days, respectively, and 40.1% and 60.3% in patients with severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " at 7 and 14 days, respectively140. However, this study did not include a control arm, and most of the trials of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    favilavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " were based on a small sample size. For more reliable assessment of the effectiveness of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    favilavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " for treating \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", large-scale randomized controlled trials should be conducted.</br></br>\n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lopinavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ritonavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " were reported to have in vitro inhibitory activity against SARS-CoV and MERS-CoV141,142. Alone, the combination of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lopinavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ritonavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " had little therapeutic benefit in patients with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", but appeared more effective when used in combination with other drugs, including ribavirin and interferon beta-1b143,144. The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial, a national clinical trial programme in the UK, has stopped treatment with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lopinavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ritonavir\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " as no significant beneficial effect was observed in a randomized trial established in March 2020 with a total of 1,596 patients145. Nevertheless, other clinical trials in different phases are still ongoing elsewhere.</br></br>Immunomodulatory agents</br>SARS-CoV-2 triggers a strong immune response which may cause cytokine storm syndrome60,61. Thus, immunomodulatory agents that inhibit the excessive inflammatory response may be a potential adjunctive therapy for \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Dexamethasone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " is a corticosteroid often used in a wide range of conditions to relieve inflammation through its anti-inflammatory and immunosuppressant effects. Recently, the RECOVERY trial found \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dexamethasone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " reduced mortality by about one third in hospitalized patients with \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " who received invasive mechanical ventilation and by one fifth in patients receiving \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #43C6AC, ##F8FFAE); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    oxygen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". By contrast, no benefit was found in patients without respiratory support146.</br></br>Tocilizumab and sarilumab, two types of interleukin-6 (IL-6) receptor-specific antibodies previously used to treat various types of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    arthritis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", including \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rheumatoid arthritis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cytokine release syndrome\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", showed effectiveness in the treatment of severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " by attenuating the cytokine storm in a small uncontrolled trial147. Bevacizumab is an anti-vascular endothelial growth factor (VEGF) medication that could potentially reduce \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pulmonary oedema\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in patients with severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Eculizumab is a specific monoclonal antibody that inhibits the proinflammatory complement protein C5. Preliminary results showed that it induced a drop of inflammatory markers and C-reactive protein levels, suggesting its potential to be an option for the treatment of severe \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " (ref.148).</br></br>The interferon response is one of the major innate immunity defences against virus invasion. Interferons induce the expression of diverse interferon-stimulated genes, which can interfere with every step of virus replication. Previous studies identified type I interferons as a promising therapeutic candidate for SARS149. In vitro data showed SARS-CoV-2 is even more sensitive to type I interferons than SARS-CoV, suggesting the potential effectiveness of type I interferons in the early treatment of COVID-19 (ref.150). In China, vapor inhalation of interferon-α is included in the COVID-19 treatment guideline151. Clinical trials are ongoing across the world to evaluate the efficacy of different therapies involving interferons, either alone or in combination with other agents152.</br></br>Immunoglobulin therapy</br>Convalescent plasma treatment is another potential adjunctive therapy for COVID-19. Preliminary findings have suggested improved clinical status after the treatment153,154. The FDA has provided guidance for the use of COVID-19 convalescent plasma under an emergency investigational new drug application. However, this treatment may have adverse effects by causing antibody-mediated enhancement of infection, transfusion-associated \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute lung injury\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    allergic transfusion reactions\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br></br>Monoclonal antibody therapy is an effective immunotherapy for the treatment of some \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    viral infections\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in select patients. Recent studies reported specific monoclonal antibodies neutralizing \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " infection in vitro and in vivo155–158. Compared with convalescent plasma, which has limited availability and cannot be amplified, monoclonal antibodies can be developed in larger quantities to meet clinical requirements. Hence, they provide the possibility for the treatment and prevention of COVID-19. The neutralizing epitopes of these monoclonal antibodies also offer important information for vaccine design. However, the high cost and limited capacity of manufacturing, as well as the problem of bioavailability, may restrict the wide application of monoclonal antibody therapy.</br></br>Vaccines</br>Vaccination is the most effective method for a long-term strategy for prevention and control of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in the future. Many different vaccine platforms against SARS-CoV-2 are in development, the strategies of which include recombinant vectors, DNA, mRNA in lipid nanoparticles, inactivated viruses, live attenuated viruses and protein subunits159–161. As of 2 October 2020, ~174 vaccine candidates for COVID-19 had been reported and 51 were in human clinical trials (COVID-19 vaccine and therapeutics tracker). Many of these vaccine candidates are in phase II testing, and some have already advanced to phase III trials. A randomized double-blinded phase II trial of an adenovirus type 5-vectored vaccine expressing the SARS-CoV-2 S protein, developed by CanSino Biologicals and the Academy of Military Medical Sciences of China, was conducted in 603 adult volunteers in Wuhan. The vaccine has proved to be safe and induced considerable humoral and cellular immune response in most recipients after a single immunization162. Another vectored vaccine, ChAdOx1, was developed on the basis of chimpanzee adenovirus by the University of Oxford. In a randomized controlled phase I/II trial, it induced neutralizing antibodies against SARS-CoV-2 in all 1,077 participants after a second vaccine dose, while its safety profile was acceptable as well163. The NIAID and Moderna co-manufactured mRNA-1273, a lipid nanoparticle-formulated mRNA vaccine candidate that encodes the stabilized prefusion SARS-CoV-2 S protein. Its immunogenicity has been confirmed by a phase I trial in which robust neutralizing antibody responses were induced in a dose-dependent manner and increased after a second dose164. Regarding inactivated vaccines, a successful phase I/II trial involving 320 participants has been reported in China. The whole-virus COVID-19 vaccine had a low rate of adverse reactions and effectively induced neutralizing antibody production165. The verified safety and immunogenicity support advancement of these vaccine candidates to phase III clinical trials, which will evaluate their efficacy in protecting healthy populations from \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2 infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br></br>Future perspectives</br>COVID-19 is the third highly pathogenic human \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronavirus disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " to date. Although less deadly than \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MERS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", the rapid spreading of this highly contagious disease has posed the severest threat to global health in this century. The \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " outbreak has lasted for more than half a year now, and it is likely that this emerging virus will establish a niche in humans and coexist with us for a long time166. Before clinically approved vaccines are widely available, there is no better way to protect us from \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " than personal preventive behaviours such as social distancing and wearing masks, and public health measures, including active testing, case tracing and restrictions on social gatherings. Despite a flood of SARS-CoV-2 research published every week, current knowledge of this novel coronavirus is just the tip of the iceberg. The animal origin and cross-species infection route of SARS-CoV-2 are yet to be uncovered. The molecular mechanisms of \n",
       "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #aa9cfc, #fc9ce7); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " infection pathogenesis and virus–host interactions remain largely unclear. Intensive studies on these virological profiles of SARS-CoV-2 will provide the basis for the development of preventive and therapeutic strategies against COVID-19. Moreover, continued genomic monitoring of SARS-CoV-2 in new cases is needed worldwide, as it is important to promptly identify any mutation that may result in phenotypic changes of the virus. Finally, COVID-19 is challenging all human beings. Tackling this epidemic is a long-term job which requires efforts of every individual, and international collaborations by scientists, authorities and the public.</br></div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "entities_html = displacy.render(doc, style=\"ent\", options={\"ents\": [\"DISEASE\", \"CHEMICAL\"], \"colors\": colors})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4895e0d6-4a75-4727-90ed-1aec94a2d2bc",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (biobert)",
   "language": "python",
   "name": "biobert"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
